Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Topical Minoxidil Vaccine Interaction Profile: What Patients and Clinicians Need to Know

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Vaccine interaction / Not established; neither label mentions vaccines [1][2]
  • Products / OTC 5%: Men's Rogaine Extra Strength solution; Women's Rogaine foam [1][2]
  • Label warnings / Heart disease precaution, scalp irritation, unwanted facial hair, regrowth check [1][2]
  • Oral minoxidil / Separate prescription tablet; not the OTC topical product [4]

What do the topical minoxidil labels say?

The men's 5% solution label is for external use by men on the top of the scalp [1]. It lists heart disease as a precaution. It lists chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, swelling of hands or feet, scalp irritation or redness, unwanted facial hair, and no regrowth after 4 months under its stop-use heading [1].

The women's 5% foam label describes half a capful once daily and says results may occur at 3 months, with some women needing 6 months [2]. It also lists heart disease as a precaution, along with the same kinds of warning signs and a 6-month regrowth check [2].

The oral minoxidil tablet is a separate prescription product approved only for severe hypertension. Its label states that use to promote hair growth in any formulation is not an approved indication [4]. Rogaine topical products are sold over the counter [3].

Is there any study of topical minoxidil with vaccines?

A 2022 single-center study described 24 people who developed alopecia areata within 16 weeks after COVID-19 vaccination. Minoxidil was one of the systemic treatments used for extensive disease. The study did not test topical minoxidil 5% as an exposure or measure a minoxidil-vaccine interaction [6].

Frequently asked questions

Is there a known vaccine interaction with topical minoxidil 5%?
No interaction is established. The only vaccine-related paper cited here describes alopecia areata after COVID-19 vaccination, not an interaction with minoxidil [6].
Does topical minoxidil suppress the immune system?
The Drug Facts warning sections list local scalp and heart-related warnings; immune suppression is not among them [1][2].
Can I get a vaccine on the same day I apply topical minoxidil?
The Drug Facts texts for the men's 5% solution and women's 5% foam give no same-day timing rule [1][2].
What warning signs do the labels list?
The men's 5% solution label lists chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, swelling of hands or feet, scalp irritation or redness, unwanted facial hair, and no regrowth after 4 months under its stop-use heading [1]. The women's 5% foam label lists similar warning signs and a 6-month regrowth check [2].

References

  1. U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
  2. U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
  3. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  4. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  5. Adult Immunization Schedule by Age (Addendum updated July 2, 2025) | Vaccines & Immunizations | CDC. Adult Immunization Schedule by Age (Addendum updated July 2, 2025) | Vaccines & Immunizations | CDC
  6. Tassone F, Cappilli S, Antonelli F, Zingarelli R, Chiricozzi A, Peris K. Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study. Vaccines (Basel). 2022;10(9). Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study
Evidence overview for interactions topical minoxidil: Topical Minoxidil Vaccine Interaction Profile: What Patients and Clinicians Need to Know